Difference between revisions of "Increasing Willingness and/or Ability of Governments to Sponsor Biotech Research."

From ScenarioThinking
Jump to navigation Jump to search
Line 4: Line 4:


==Enablers:==
==Enablers:==
• Biotech has been declared a core topic of the economic policy of many governments
• Biotech has been declared a core topic of the economic policy of many governments<br>
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth<br>
• Lack of private venture capital in certain countries triggering calls for government sponsorship
• Lack of private venture capital in certain countries triggering calls for government sponsorship<br>
• Worldwide diseases
• Worldwide diseases<br>
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine<br>
• Few other alternatives for Research Sponsorship
• Few other alternatives for Research Sponsorship<br>
 
 
 


==Inhibitors:==
==Inhibitors:==

Revision as of 13:09, 2 December 2005

Description:

Many governments are willing to support and sponsor fundamental research in biotech by massive funds, many have declared biotech a core issue in their economic strategy and many are trying to attract biotech companies to move production sites and research activities to the territory of their countries. A biotech company is almost always welcome.


Enablers:

• Biotech has been declared a core topic of the economic policy of many governments
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth
• Lack of private venture capital in certain countries triggering calls for government sponsorship
• Worldwide diseases
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine
• Few other alternatives for Research Sponsorship

Inhibitors:

• Budgetary limitations • Exploding healthcare costs • Priorities other than biotech • Other promising opportunities for investment and sponsorship

Paradigms:

• Perception of biotechnology as a core topic for the competitiveness of a nation

Experts:

• Ernst & Young, biotech Report

Timing:

• 2000 – 2005 Biotech strategies by several countries • 2001: Healthcare Spending by US Goverment passes 20% of governmental budget • 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe • 11/2002: First People suffering from SARS identified in Province of Guangdong, China • 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution


Web Resources:

• WHO